Paul Rugman
About
Paul Rugman is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Molecular Biology.
According to data from OpenAlex, Paul Rugman has authored 21 papers receiving a total of 776 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 8 papers in Physiology and 6 papers in Molecular Biology. Recurrent topics in Paul Rugman's work include Chronic Obstructive Pulmonary Disease (COPD) Research (8 papers), Asthma and respiratory diseases (8 papers) and Respiratory and Cough-Related Research (4 papers). Paul Rugman is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (8 papers), Asthma and respiratory diseases (8 papers) and Respiratory and Cough-Related Research (4 papers). Paul Rugman collaborates with scholars based in United Kingdom, United States and Spain. Paul Rugman's co-authors include Mona Bafadhel, Christopher E. Brightling, Dhananjay Desai, Richard May, Joanne Woods, Paul Newbold, Margaret McCormick, Salman Siddiqui, Vijay Mistry and Camille Doe and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and CHEST Journal.
In The Last Decade
Paul Rugman
21 papers receiving 766 citations
Peers
Paul Rugman
Stelios Pavlidis United Kingdom
Kristy Nichol Australia
Rochelle Palmay New Zealand
Fahd Alhamdan Germany
Jessica Ahern Australia
Timothy Oates United Kingdom
Lakshitha P Gunawardhana Australia
Sandra Grumelli Argentina
Madison G. Boswell United States
Kęstutis Malakauskas Lithuania
Citations per year, relative to Paul Rugman Paul Rugman (= 1×)
peers
Stelios Pavlidis
Countries citing papers authored by Paul Rugman
Since
Specialization
Citations
This map shows the geographic impact of Paul Rugman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Rugman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Rugman more than expected).
Fields of papers citing papers by Paul Rugman
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Paul Rugman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Rugman. The network helps show where Paul Rugman may publish in the future.
Co-authorship network of co-authors of Paul Rugman
This figure shows the co-authorship network connecting the top 25 collaborators of Paul Rugman. A scholar is included among the top collaborators of Paul Rugman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Rugman. Paul Rugman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kim, Jae‐Weon, Rutie Yin, Fabian Trillsch, et al.. (2022). A randomized Phase III trial of durvalumab with chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer (DUO-O): Updated trial endpoint and inclusion of China cohort (329). Gynecologic Oncology. 166. S170–S170.
2.
Harter, Philipp, Mariusz Bidziński, Nicoletta Colombo, et al.. (2019). DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.. Journal of Clinical Oncology. 37(15_suppl). TPS5598–TPS5598.
3.
Diver, Sarah, Matt Richardson, Koirobi Haldar, et al.. (2019). Sputum microbiomic clustering in asthma and chronic obstructive pulmonary disease reveals a Haemophilus‐predominant subgroup. Allergy. 75(4). 808–817.
4.
Rugman, Paul, et al.. (2018). Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma. SHILAP Revista de lepidopterología.
5.
Ghebre, Michael A., Sarah Diver, Dhananjay Desai, et al.. (2018). Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles. Journal of Allergy and Clinical Immunology. 141(6). 2027–2036.e12.
6.
Bateman, Eric D., et al.. (2018). Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma. Drug Design Development and Therapy. Volume 12. 1093–1106.
7.
Dean, Emma, Udai Banerji, Jan H.M. Schellens, et al.. (2018). A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK. Cancer Chemotherapy and Pharmacology. 81(5). 873–883.
8.
Ghebre, Michael A., Sarah Diver, Dhananjay Desai, et al.. (2018). Overlapping biologic exacerbation clusters in asthma and chronic obstructive pulmonary disease have distinct sputum mediator and microbiome profiles. PA5468–PA5468.
9.
Turner, Nicholas C., Anne Armstrong, Yamil Alonso Lopez Chuken, et al.. (2017). BEECH: A randomised Phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Annals of Oncology. 28. v76–v76.
10.
Litton, Jennifer K., Rhys Williams, Pamela T. Soliman, et al.. (2017). Phase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer. Annals of Oncology. 28. v130–v131.
11.
Banerji, Udai, Emma Dean, José Alejandro Pérez Fidalgo, et al.. (2015). A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers.. Journal of Clinical Oncology. 33(15_suppl). 2500–2500.
12.
Dean, Emma, Udai Banerji, Jan H.M. Schellens, et al.. (2015). Results of OAK: A phase 1, open-label, multicentre study to compare two dosage forms of AZD5363 and to explore the effect of food on the pharmacokinetic (PK) exposure, safety, and tolerability of AZD5363 in patients with advanced solid malignancies.. Journal of Clinical Oncology. 33(15_suppl). 2577–2577.
13.
Ghebre, Michael A., Mona Bafadhel, Dhananjay Desai, et al.. (2014). Biological clustering supports both “Dutch” and “British” hypotheses of asthma and chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology. 135(1). 63–72.e10.
14.
Vanfleteren, Lowie E.G.W., Frits M.E. Franssen, Martijn A. Spruit, et al.. (2011). Determinants Of Carotid Intima-Media Thickness In Patients With COPD: The Ciroco Study. A2608–A2608.
15.
Doe, Camille, Mona Bafadhel, Salman Siddiqui, et al.. (2010). Expression of the T Helper 17-Associated Cytokines IL-17A and IL-17F in Asthma and COPD. CHEST Journal. 138(5). 1140–1147.
16.
Bafadhel, Mona, Roshan Siva, Michael McCormick, et al.. (2009). Sputum IL-5 Concentration Is Associated with a Sputum Eosinophilia and Attenuated by Corticosteroid Therapy in COPD. Respiration. 78(3). 256–262.
17.
Bafadhel, Mona, Sharon L. McKenna, Colm J. Reid, et al.. (2009). The Sensitivity and Specificity of Peripheral Blood Eosinophilia To Predict Sputum Eosinophilia in COPD Subjects.. A1479–A1479.
18.
Sapey, Elizabeth, Ali Ahmad, D Bayley, et al.. (2009). Imbalances Between Interleukin-1 and Tumor Necrosis Factor Agonists and Antagonists in Stable COPD. Journal of Clinical Immunology. 29(4). 508–516.
19.
Sapey, Elizabeth, Ali Ahmad, D Bayley, et al.. (2009). Imbalances between Interleukin-1 and Tumour Necrosis Factor Agonists and Antagonists in Stable COPD.. A2884–A2884.
20.
Hutchings, Andrew, et al.. (1995). The 18th Meeting of the British Inflammation Research Association held at the University of Southampton on 14–15 April, 1994. Inflammation Research. 44(2). 59–63.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Stelios Pavlidis Breakdown of academic impact, for papers by Kristy Nichol Breakdown of academic impact, for papers by Rochelle Palmay Breakdown of academic impact, for papers by Fahd Alhamdan Breakdown of academic impact, for papers by Jessica Ahern Breakdown of academic impact, for papers by Timothy Oates Breakdown of academic impact, for papers by Lakshitha P Gunawardhana Breakdown of academic impact, for papers by Sandra Grumelli Breakdown of academic impact, for papers by Madison G. Boswell Breakdown of academic impact, for papers by Kęstutis Malakauskas